Last reviewed · How we verify
Xilonix
At a glance
| Generic name | Xilonix |
|---|---|
| Also known as | MABp1, CA-18C3 |
| Sponsor | Janssen Research & Development, LLC |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | discontinued |
Approved indications
Common side effects
Key clinical trials
- A Phase I Study of Onivyde and 5-FU in Combination With Xilonix for Advanced Pancreatic Cancer With Cachexia (Phase 1)
- A Phase II Open Label Study of Xilonix in Subjects With Pyoderma Gangrenosum (Phase 2)
- A Double Blind, Placebo Controlled Pivotal Phase III Study Evaluating Xilonix™ in Symptomatic Colorectal Cancer Patients Refractory to Standard Therapy (Phase 3)
- Phase III Double-blinded, Placebo Controlled Study of Xilonix™ for Improving Survival in Metastatic Colorectal Cancer (Phase 3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |